$Veru(VERU)$
VERU received FDA clarity supporting enobosarm plus GLP-1 RA as a combination obesity therapy, with incremental fat loss accepted as a primary endpoint; following positive Phase 2b QUALITY results showing preserved lean mass and physical function, Veru will initiate the Phase 2 PLATEAU trial in Q1 2026, backed by $23.4M in recent financing
感觉是鸡肋。钱也不够烧。